NCT02856815已完成2 期
Randomized, Open-label, Multi-center and Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in the Patients Undergone TACE for Intermediate Stage Hepatocellular Carcinoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 76
- 试验地点
- 6
- 主要终点
- Recurrence Free Survival (RFS)
研究概览
简要总结
To evaluate the efficacy and safety of 'Immuncell-LC group' and 'non-treatment group' in the patients undergone Transarterial Chemoembolization for intermediate stage hepatocellular carcinoma
详细描述
ILC-IIT-05 is randomized, open-label, multi-center phase 2 clinical trial. To confirm clinical efficacy and safety between 'Immuncell-LC group' and 'non-treatment group', primary outcome, recurrence free survival(RFS) will be evaluated.
For secondary outcome, overall survival(OS), changes of Alpha Feto Protein(AFP), correlation of between myeloid-derived suppressor cell change and prognosis, adverse event, ECOG-PS and hematological examination will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have consented to the study by providing signature of self
- •Patients who are more than 20 and less than 80 years old
- •Child-Pugh Class should be A(score 5-6) or B(score 7-8)
- •ECOG Performance Status (ECOG-PS) score is less than 1 or equal to
- •Patients who have been diagnosed with BCLC stage B hepatocellular carcinoma by pathological/radiological test(Dynamic contrast-enhanced CT or Dynamic MRI) and tumor removal has been confirmed after TACE (When patients have been diagnosed with recurrence of hepatocellular carcinoma after surgery or local treatment, if conditions are same as above, patients could be included)
- •Patients who satisfy the following conditions of the blood test and kidney, liver function test
- •Absolute neutrophil count > 500/µL
- •Hemoglobin ≥ 8.5 g/dL
- •Platelet count > 50,000/µL
- •Blood Creatinine ≤ 1.5xupper normal limit
- •Total bilirubin < 3mg/dL
- •Albumin ≥ 2.8g/dL
排除标准
- •Patients who have been confirmed with residual tumor or extrahepatic metastases
- •Patients who have lymph node metastases or portal vein, hepatic vein invasion
- •Patients who have a history of treatments or are in conditions as below
- •Liver transplantation
- •From Informed consent form sign date, systemic chemotherapy in 4 weeks or ongoing adverse drug reactions from anticancer drug in 6 weeks
- •External beam radiation, immunotherapy, molecular target therapy
- •More than 2 times of systemic chemotherapy
- •Biliary reconstruction or endoscopic biliary treatment
- •Patients who have a history of auto-immune diseases (Ex. Rheumatoid Arthritis, Systemic Lupus Erythematosus, Vasculitis, Multiple sclerosis, Adolescent Insulin-Dependent Diabetes Mellitus, etc.)
- •Patients who have a history of malignant tumors in the recent 5 years prior to the study except hepatocellular carcinoma
- •Patients who participated in another clinical trial and conducted treatment in 4 weeks or have a plan for administration of another clinical trial treatment since Informed consent form sign date
- •Patients who have uncontrollable or serious disease
- •Pregnant women or nursing mother
- •Patients who intend to get pregnant during the study
结局指标
主要结局
Recurrence Free Survival (RFS)
时间窗: baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject
Every 12 weeks from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject
次要结局
- Overall Survival (OS)(baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject)
- Hematological examination(Every 12 weeks from the baseline until 4 weeks after the last dose of immunotherapy)
- Change of Alpha Feto Protein (AFP) level(Every 12 weeks from the baseline until 44 weeks, and then every 3 months until the data cut-off date or 12 months from baseline of last subject)
- Correlation of between Myeloid-derived Suppressor Cell change and Prognosis(Every 12 weeks from the baseline until 4 weeks after the last dose of immunotherapy)
- Adverse event(From the time the patient provided written informed consent until drop-out or the end of the study or at least 4 weeks after the last dose of immunotherapy)
- Eastern Cooperative Oncology Group Performance Status (ECOG-PS)(From the time the patient provided written informed consent until drop-out or the end of the study or 4 weeks after the last dose of immunotherapy)
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
不适用
Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric CancerRelapsed or Advanced Gastric AdenocarcinomaGastro-esophageal Junction CancerNCT05053295Gangnam Severance Hospital20
Unknown
2 期
The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal CancerMetastatic Colorectal CancerNCT03220984Gangnam Severance Hospital28
终止
1 期
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)Carcinoma, Non-Small-Cell LungNCT03337698Hoffmann-La Roche314
已完成
3 期
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised SubjectsHSV InfectionNCT03073967AiCuris Anti-infective Cures AG158
已完成
3 期
Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma PatientsHepatocellular CarcinomaNCT00699816GC Cell Corporation230